Screener
TG Therapeutics TGTX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's restricted cash?
- TG Therapeutics (TGTX) reported restricted cash of $1.36M in Q2 2026.
- How has TG Therapeutics's restricted cash changed year-over-year?
- TG Therapeutics's restricted cash increased by 3.6% year-over-year, from $1.32M to $1.36M.
- What is the long-term trend for TG Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), TG Therapeutics's restricted cash has grown at a 1.3% compound annual growth rate (CAGR), from $1.26M to $1.34M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about TG Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude